The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients
Abstract
CONTEXT: Adrenocortical carcinomas (ACC) are rare tumors with a poor prognosis. Few reports concerning large and homogeneous series are available. OBJECTIVE: We aimed to determine the clinical characteristics and outcome of ACC and to identify prognostic factors. DESIGN AND SETTING: This study is a descriptive and multivariate analysis of a cohort from a single endocrinology center. PATIENTS: A total of 202 consecutive patients with ACC were studied. RESULTS: The sex ratio (female to male) was 2.7. Mean age at diagnosis was 44 +/- 16 yr (range, 11-88 yr). We found that 154 patients (76%) had hypersecreting tumors [mostly cortisol and androgens (47%), cortisol alone (27%), or androgens alone (6%)] and 43 patients (21%) had metastases at diagnosis. At initial staging or during follow-up, 85 patients (42%) had liver metastases, 79 patients (39%) had lung metastases, and 20 patients had bone metastases (10%). The survival rate was 37% at 5 yr. Multivariate analysis identified the following independent prognostic factors associated with shorter survival: older age at diagnosis [hazard ratio (HR), 1.03; P < 0.0001], initial MacFarlane extension stages 3 (HR, 4.42; P = 0.005) and 4 (HR, 7.93; P < 0.0001), and cortisol hypersecretion (HR, 3.90; P < 0.0001). Treatment with 1,1-dichlorodiphenildichloroethane (o,p'DDD) in the 3 months after surgery increased the survival rate of patients with cortisol-secreting tumors (HR, 0.40; P = 0.04). CONCLUSION: This study highlights the better prognosis of ACC diagnosed at a noninvasive local stage, the particularly poor prognosis of patients with cortisol-secreting tumors, and the beneficial effect of o,p'DDD therapy in this subgroup of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The impact of the functional status and clinical features of ACCs on survival is unclear (132,133).”
From Adrenal incidentaloma (2020) · cites this paper as [133]
In the citing paper
“Biochemically or clinically apparent adrenocortical hormone production is evident in up to 45% to 70% (9, 10, 85).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“Autonomous aldosterone secretion (which classically leads to hypertension and hypokalemia) is rare in ACC (85, 86).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“At the time of presentation, ACCs are generally large tumors, measuring on average 10 to 13 cm (9, 85, 89).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“Hypercortisolism is the most common presentation of patients presenting with hormone excess (50%–80% of hormone-secreting ACCs), causing classic symptoms including plethora, diabetes mellitus, muscle weakness/atrophy, and osteoporosis.”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“some recent studies identified cortisol production as an adverse prognostic factor (12, 85, 244).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
Citations
Cites
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10 · Cited by 2,097
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt‐Rasmussen, U., Hagen, C., Jørgensen, J. O. L., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 763
Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474
Self-citationBerruti, A., Terzolo, M., Sperone, P., Pia, A. R., Casa, S. D., Gross, D. J., Carnaghi, C., Casali, P. G., Porpiglia, F., Mantero, F., et al. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01025 · Cited by 308
Gicquel, C., BERTAGNA, X. Y., Gaston, V., Coste, J., Louvel, A., Baudin, É., Bertherat, J. Y., Chapuis, Y., Duclos, J. M., Schlumberger, M. J., et al. (2001) · PubMed · Cited by 285
Self-citationHutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90219-1 · Cited by 277
Hutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90220-8 · Cited by 271
Macfarlane, D. A. (1958) · PubMed · Cited by 266
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 446
Adjuvant Mitotane in Adrenocortical Carcinoma
Bertherat, J. Y., Coste, J., & BERTAGNA, X. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076267 · Cited by 50
Self-citationWanis, K. N., & Kanthan, R. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0527-4 · Cited by 49
Barreau, O., de Reyniès, A., Wilmot-Roussel, H., Guillaud-Bataille, M., Auzan, C., René-Corail, F., Tissier, F., Dousset, B. E., BERTAGNA, X. Y., Bertherat, J. Y., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1588 · Cited by 49
Self-citationWnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice
Borges, K. S., Pignatti, E., Leng, S., Kariyawasam, D., Ruiz‐Babot, G., Ramalho, F. S., Taketo, M. M., Carlone, D. L., & Breault, D. T. (2020) · Oncogene · doi:10.1038/s41388-020-1358-5 · Cited by 52
Current management options for recurrent adrenocortical carcinoma
Sidhu, S. B., Glover, A. R., Ip, Zhao, J., Soon, & Robinson (2013) · OncoTargets and Therapy · doi:10.2147/ott.s34956 · Cited by 46
Poli, G., Ruggiero, C., Cantini, G., Canu, L., Baroni, G., Armignacco, R., Jouinot, A., Santi, R., Ercolino, T., Ragazzon, B., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01717 · Cited by 46
Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis
Abiven, G., Coste, J., Tissier, F., Groussin, L., BILLAUD, L., Dousset, B. E., Goffinet, F., BERTAGNA, X. Y., Bertherat, J. Y., & Raffin‐Sanson, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0412 · Cited by 46
Self-citationCurrent and Emerging Therapies for Advanced Adrenocortical Carcinoma
Tacon, L. J., Prichard, R. S., Soon, P. S. H., Robinson, B. G., Clifton-Bligh, R. J., & Sidhu, S. B. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0270 · Cited by 42
Asare, E. A., Wang, T. S., Winchester, D. P., Mallin, K., Kebebew, E., & Sturgeon, C. (2014) · Surgery · doi:10.1016/j.surg.2014.08.018 · Cited by 45
Puglisi, S., Calabrese, A., Ferraù, F., Violi, M. A., Laganà, M., Grisanti, S., Ceccato, F., Scaroni, C. M., Dalmazi, G. D., Stigliano, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad199 · Cited by 44
Actual 10‐year survivors following resection of adrenocortical carcinoma
Tran, T. B., Postlewait, L. M., Maithel, S. K., Prescott, J. D., Wang, T. S., Glenn, J. A., Phay, J. E., Keplinger, K. M., Fields, R. C., Jin, L. X., et al. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24439 · Cited by 44
Current Status and Future Targeted Therapy in Adrenocortical Cancer
Alyateem, G., & Nilubol, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.613248 · Cited by 42
Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?
Baudin, É., Leboulleux, S., Ghuzlan, A. A., Chougnet, C., Young, J., Deandreis, D., Dumont, F., Dechamps, F., Caramella, C., Chanson, P., et al. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0094-2 · Cited by 42
Mizdrak, M., Kurir, T. T., & Božić, J. (2021) · Biomedicines · doi:10.3390/biomedicines9020174 · Cited by 44
Developing treatment for adrenocortical carcinoma
Kerkhofs, T. M. A., Ettaieb, M. H. T., Hermsen, I. G. C., & Haak, H. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0318 · Cited by 41
P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model
Batisse‐Lignier, M., Sahut‐Barnola, I., Tissier, F., Dumontet, T., Mathieu, M., Drelon, C., Pointud, J.-C., Damon‐Soubeyrand, C., Marceau, G., Kemeny, J.-L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.54 · Cited by 42
Self-citationDecision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options
Puglisi, S., Perotti, P., Cosentini, D., Roca, E., Basile, V., Berruti, A., & Terzolo, M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1510325 · Cited by 42
Surgery for adrenocortical carcinoma: When and how?
Sinclair, T. J., Gillis, A., Alobuia, W. M., Wild, H. B. H., & Kebebew, E. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101408 · Cited by 42
Sigala, S., Bothou, C., Pentón, D., Abate, A., Peitzsch, M., Cosentini, D., Tiberio, G. A. M., Bornstein, S. R., Berruti, A., & Hantel, C. (2022) · Cells · doi:10.3390/cells11091439 · Cited by 41
Fiorentini, C., Fragni, M., Perego, P., Vezzoli, S., Bonini, S. A., Tortoreto, M., Galli, D., Claps, M., Tiberio, G. A. M., Terzolo, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2414 · Cited by 41
Surgical treatment of adrenal carcinoma
Gaujoux, S., Weinandt, M., Bonnet, S., Reslinger, V., Bertherat, J. Y., & Dousset, B. E. (2017) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2017.06.010 · Cited by 38
Self-citationCurative Surgical Resection of Adrenocortical Carcinoma
Kim, Y., Margonis, G. A., Prescott, J. D., Tran, T. B., Postlewait, L. M., Maithel, S. K., Wang, T. S., Glenn, J. A., Hatzaras, I. S., Shenoy, R. S., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001527 · Cited by 37
d’Alva, C. B., Abiven, G., Viallon, V., Groussin, L., Dugué, M. A., BERTAGNA, X. Y., & Bertherat, J. Y. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0324 · Cited by 36
Self-citationDaher, M., Varghese, J. M., Gruschkus, S. K., Jiménez, C., Waguespack, S. G., Bedrose, S. S. D., Altameemi, L., Bazerbashi, H., Naing, A., Subbiah, V., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac046 · Cited by 35
The molecular basis of adrenocortical cancer
Lehmann, T. P., & Wrzesiński, T. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.02.009 · Cited by 34
Hadjadj, D., Kim, S.-J., Denecker, T., Driss, L. B., Cadoret, J., Maric, C. A., Baldacci, G., & Fauchereau, F. (2017) · Aging · doi:10.18632/aging.101356 · Cited by 37
Liang, J., Liu, Z., Wei, X., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., Lu, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6389-3 · Cited by 35
Lin, C.-W., Chang, Y., & Pu, H. (2012) · Toxicology · doi:10.1016/j.tox.2012.04.007 · Cited by 34
Adrenocortical Cancer Treatment
Patalano, A., Brancato, V., & Mantero, F. (2009) · Hormone Research in Paediatrics · doi:10.1159/000178049 · Cited by 34
Emerging drugs for adrenocortical carcinoma
Berruti, A., Ferrero, A., Sperone, P., Daffara, F., Reimondo, G., Papotti, M. G., Dogliotti, L., Angeli, A., & Terzolo, M. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.497 · Cited by 34
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies
Lerário, A. M., Mohan, D. R., & Hammer, G. D. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac012 · Cited by 36
Srougi, V., Bancos, I., Daher, M., Lee, J. E., Graham, P. H., Karam, J. A., Henriquez, A., McKenzie, T. J., Sada, A., Bourdeau, I., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab865 · Cited by 34
Adrenocortical carcinoma: a literature review
Thampi, A., Shah, E., Elshimy, G., & Correa, R. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.12.28 · Cited by 32
Leboulleux, S., Deandreis, D., Escourrou, C., Ghuzlan, A. A., Bidault, F., Auperin, A., Travagli, J. P., Lumbroso, J., Schlumberger, M. J., & Baudin, É. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0666 · Cited by 31
Zhu, J., Zheng, Z., Shen, J., Lian, X., Miao, Z., Shen, J., & Zhang, F. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01533-3 · Cited by 30
Rizk‐Rabin, M., Assié, G., René-Corail, F., Perlemoine, K., Hamzaoui, H., Tissier, F., Lieberherr, M., BERTAGNA, X. Y., Bertherat, J. Y., & Bouizar, Z. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2924 · Cited by 30
Self-citationAktuelle TNM-Klassifikationssysteme für das Nebennierenkarzinom
Faßnacht, M., Wittekind, C., & Allolio, B. (2010) · Der Pathologe · doi:10.1007/s00292-010-1306-1 · Cited by 29
Jong, M. C. D., Mihai, R., & Khan, S. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05868-6 · Cited by 28
Terzolo, M., & Faßnacht, M. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0260 · Cited by 30
The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study
Sada, A., Foster, T. R., Al-Ward, R., Sawani, S., Charchar, H. L. S., Pishdad, R., Ben-Shlomo, A., Dy, B. M., Lyden, M. L., Bergsland, E. K., et al. (2023) · Surgery · doi:10.1016/j.surg.2023.04.070 · Cited by 28
Open adrenalectomy in the era of laparoscopic surgery: a review
Taffurelli, G., Ricci, C., Casadei, R., Selva, S., & Minni, F. (2017) · Updates in Surgery · doi:10.1007/s13304-017-0440-1 · Cited by 30
Sun, N., Kunzke, T., Sbiera, S., Kircher, S., Feuchtinger, A., Aichler, M., Herterich, S., Ronchi, C. L., Weigand, I., Schlegel, N., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.306043 · Cited by 28
Freire, D. S., Siqueira, S. A. C., Zerbini, M. C. N., WAJCHENBERG, B. L., Corrêa‐Giannella, M. L., Lucón, A. M., & Pereira, M. A. A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12174 · Cited by 26
Improving Outcomes in Adrenocortical Cancer: An Australian Perspective
Ip, J. C. Y., Pang, T., Glover, A. R., Soon, P. S. H., Clarke, S. J., Richardson, A. J., Campbell, P. R., Robinson, B. G., & Sidhu, S. B. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4133-4 · Cited by 26
Adrenocortical carcinoma secreting cortisol, androgens and aldosterone: a case report
Peppa, Μ., Pikounis, V., Papaxoinis, G., Macheras, A., Economopoulos, T., Raptis, S., & Hadjidakis, D. (2009) · Cases Journal · doi:10.4076/1757-1626-2-8951 · Cited by 26
Hantel, C., Jung, S., Mussack, T., Reincke, M., & Beuschlein, F. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0439 · Cited by 26
Suzuki, S., Minamidate, T., Shiga, A., Ruike, Y., Ishiwata, K., Naito, K., Ishida, A., Deguchi, H., Fujimoto, M., Koide, H., et al. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00652-y · Cited by 26
Surgical Management of Adrenocortical Carcinoma: Current Highlights
Cavallaro, G., Tarallo, M., Chiappini, A., Crocetti, D., Polistena, A., Petramala, L., Sibio, S., Toma, G. D., Fiori, E., & Letizia, C. (2021) · Biomedicines · doi:10.3390/biomedicines9080909 · Cited by 23
Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma
Clay, M. R., Pinto, E. M., Fishbein, L. M., Else, T., & Kiseljak‐Vassiliades, K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab866 · Cited by 24
Kerdivel, G., Amrouche, F., Calméjane, M.-A., Carallis, F., Hamroune, J., Hantel, C., Bertherat, J. Y., Assié, G., & Boeva, V. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01534-5 · Cited by 23
Self-citationBerruti, A., Libé, R., Laganà, M., Ettaieb, H., Sukkari, M. A., Bertherat, J. Y., Feelders, R. A., Grisanti, S., Cartry, J., Mazziotti, G., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0026 · Cited by 23
Self-citationMalayeri, A. A., Zaheer, A., Fishman, E. K., & Macura, K. J. (2013) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e31828b690d · Cited by 22
Surgical Management of Adrenocortical Carcinoma
Ranvier, G. G. F., & Inabnet, W. B. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.008 · Cited by 22
Zhang, F., Zhang, F., Liu, Z., Wu, K., Zhu, Y., & Lu, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01050-0 · Cited by 24
Virilization of a female infant by a maternal adrenocortical carcinoma
Morris, L. F., Park, S., Daskivich, T. J., Churchill, B. M., Rao, C. V., Lei, Z. M., Martinez, D. S., & Yeh, M. W. (2011) · Endocrine Practice · doi:10.4158/ep10209.cr · Cited by 22
Lai, G., Liu, H., Deng, J., Li, K., Zhang, C., Zhong, X., & Xie, B. (2023) · Cells · doi:10.3390/cells12050755 · Cited by 22
Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment
Stigliano, A., Cerquetti, L., Sampaoli, C., Bucci, B., & Toscano, V. (2012) · Journal of Oncology · doi:10.1155/2012/408131 · Cited by 19
Clinical and molecular prognostic factors in adrenocortical carcinoma
Libé, R. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02900-0 · Cited by 21
The Immunotherapy Landscape in Adrenocortical Cancer
Pegna, G. J., Roper, N., Kaplan, R. N., Bergsland, E. K., Kiseljak‐Vassiliades, K., Habra, M. A., Pommier, Y. G., & Rivero, J. D. (2021) · Cancers · doi:10.3390/cancers13112660 · Cited by 22
Liang, J., Liu, Z.-H., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., Wei, X., Lu, Y., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02141-2 · Cited by 20
Emerging Therapy for Adrenocortical Carcinoma
Aufforth, R., & Nilubol, N. (2014) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.13 · Cited by 20
Maiter, D. M., Bex, M., Vroonen, L., T'Sjoen, G. G., Gil, T., Banh, C., & Chadarévian, R. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.02.005 · Cited by 20
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
van Koetsveld, P. M., Creemers, S. G., Dogan, F., Franssen, G. J. H., de Herder, W. W., Feelders, R. A., & Hofland, L. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz001 · Cited by 21
Liang, J., Liu, Z., Pei, T., Xiao, Y., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., et al. (2020) · Disease Markers · doi:10.1155/2020/5354825 · Cited by 20
van Koetsveld, P. M., Vitale, G., Feelders, R. A., Waaijers, M., Sprij-Mooij, D. M., de Krijger, R. R., Speel, E. M., Hofland, J., Lamberts, S. W. J., de Herder, W. W., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0217 · Cited by 20
Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors
Drougat, L., Omeiri, H., Lefèvre, L., & Ragazzon, B. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00096 · Cited by 19
Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma
Hantel, C., Lewrick, F., Reincke, M., Süss, R., & Beuschlein, F. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0427 · Cited by 19
Choi, Y. M., Kwon, H., Jeon, M. J., Sung, T., Hong, S. J., Kim, T. Y., Kim, W. B., Shong, Y. K., Lee, J., Song, D. E., et al. (2016) · Medicine · doi:10.1097/md.0000000000003736 · Cited by 19
Androgen- and Estrogen-Secreting Adrenal Cancers
Cavlan, D., Bharwani, N., & Grossman, A. B. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.016 · Cited by 19
Genetics of adrenocortical tumours
Åkerström, T., Carling, T., Beuschlein, F., & Hellman, P. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12452 · Cited by 20
Rossi, C., Cicalini, I., Verrocchio, S., Dalmazi, G. D., Federici, L., & Bucci, I. (2020) · Biomedicines · doi:10.3390/biomedicines8090314 · Cited by 21
Chagpar, R., SIPERSTEIN, A. E., & Berber, E. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.02.009 · Cited by 18
Epidemiology of Adrenocortical Carcinoma
Faßnacht, M., & Allolio, B. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_3 · Cited by 18
Ławnicka, H., Kowalewicz‐Kulbat, M., Sicińska, P., Kazimierczuk, Z., Grieb, P., & Stepien, H. (2010) · Cell and Tissue Research · doi:10.1007/s00441-010-0960-1 · Cited by 18
Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound
Bauditz, J., Quinkler, M. O., Beyersdorff, D., & Wermke, W. (2008) · Oncology Reports · doi:10.3892/or.19.5.1135 · Cited by 17
Risk of Adrenocortical Carcinoma in Adrenal Tumours Greater than 8 cm
Abdel‐Aziz, T., Parameswaran, R., Sadler, G., Weaver, A., & Mihai, R. (2014) · World Journal of Surgery · doi:10.1007/s00268-014-2912-5 · Cited by 17
Characteristics of adrenocortical carcinoma in South Korea: a registry-based nationwide survey
Lim, J. S., Lee, S., Kim, J. H., Kim, J. H., & _, _. (2020) · Endocrine Connections · doi:10.1530/ec-20-0196 · Cited by 17
Balderrama-Brondani, V., Lacombe, A. M. F., Mariani, B. M. P., Montenegro, L. R., Soares, I. C., Neto, J. E. B., Tanno, F. Y., Srougi, V., Chambo, J. L., Mendonca, B. B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031238 · Cited by 17
Boilève, A., Mathy, E., Roux, C., Faron, M., Hadoux, J., Tselikas, L., Ghuzlan, A. A., Hescot, S., Leboulleux, S., de Baère, T., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab449 · Cited by 17
Adrenocortical carcinoma: What the surgeon needs to know. Case report and literature review
Benassai, G., Desiato, V., Benassai, G., Bianco, T., Sivero, L., Compagna, R., Vigliotti, G., Limite, G., Amato, B., & Quarto, G. (2014) · International Journal of Surgery · doi:10.1016/j.ijsu.2014.05.030 · Cited by 16
Glintborg, D., Altinok, M. L., Petersen, K. R., & Ravn, P. (2015) · BMJ Case Reports · doi:10.1136/bcr-2014-204797 · Cited by 16
MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma
Pereira, S. S., Monteiro, M. P., Bourdeau, I., Lacroix, A., & Pignatelli, D. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0976 · Cited by 16
Adrenal disorders in pregnancy, labour and postpartum – an overview
Manoharan, M., Sinha, P., & Sibtain, S. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1648395 · Cited by 17
Personalized Care of Patients with Adrenocortical Carcinoma: A Comprehensive Approach
Miller, B. S., & Else, T. (2017) · Endocrine Practice · doi:10.4158/ep161719.ra · Cited by 15
Diagnosis, treatment, and survival analysis of adrenocortical carcinomas: a multicentric study
Souteiro, P., Donato, S., Costa, C. F., Pereira, C. A., Simões‐Pereira, J., Oliveira, J. M., Belo, S., Santos, A. P., Cardoso, H., Leite, V. A. P. H., et al. (2019) · HORMONES · doi:10.1007/s42000-019-00161-1 · Cited by 14
Baechle, J. J., Smith, P. M., Solórzano, C. C., Tran, T. B., Postlewait, L. M., Maithel, S. K., Prescott, J. D., Pawlik, T. M., Wang, T. S., Glenn, J. A., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09562-8 · Cited by 15
Xenograft models for adrenocortical carcinoma
Hantel, C., & Beuschlein, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.05.031 · Cited by 15
Open versus minimally invasive surgery for suspected adrenocortical carcinoma
Buller, D. M., Hennessey, A. M., & Ristau, B. T. (2021) · Translational Andrology and Urology · doi:10.21037/tau.2020.01.11 · Cited by 15
Adjuvant Mitotane for Adrenocortical Cancer—Working through Uncertainty
Terzolo, M., Faßnacht, M., Ciccone, G., Allolio, B., & Berruti, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0120 · Cited by 14
The indeterminate adrenal mass
Harrison, B. J. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0845-0 · Cited by 14
Molecular markers and targeted therapies for adrenocortical carcinoma
Xu, Y., Qi, Y., Zhu, Y., Ning, G., & Huang, Y. (2013) · Clinical Endocrinology · doi:10.1111/cen.12358 · Cited by 13
Prognostic factors in adrenocortical carcinoma: data from a large Polish series
Nowak, K. M., Samsel, R., Cichocki, A. S., Ambroziak, U., Roszkowska‐Purska, K., Łebek-Szatańska, A., Koperski, Ł., Otto, M., Zgliczyński, W., & Papierska, L. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4260 · Cited by 13
Link between steroidogenesis, the cell cycle, and PKA in adrenocortical tumor cells
Rizk‐Rabin, M., Chaoui-Ibadioune, S., Vaczlavik, A., Ribes, C., Polak, M., Ragazzon, B., & Bertherat, J. Y. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110636 · Cited by 13
Self-citationExpression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis
Zhu, Y., Xu, Y., Chen, D., Zhang, C., Rui, W., Zhao, J., Zhu, Q., Wu, Y., Shen, Z., Wang, W., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1130-1 · Cited by 14
Adrenocortical carcinoma: Single center experience
Şişman, P., Şahin, A. B., Peynirci, H., Cander, S., Gül, Ö. Ö., Ertürk, E., & Ersoy, C. (2017) · Urology Research and Practice · doi:10.5152/tud.2017.81598 · Cited by 13
Ayabe, R. I., Narayan, R. R., Ruff, S. M., Wach, M. M., Lo, W. M., Nierop, P. M. H., Steinberg, S. M., Ripley, R. T., Davis, J. L., Koerkamp, B. G., et al. (2019) · HPB · doi:10.1016/j.hpb.2019.07.002 · Cited by 12
Incidence, Treatment, and Survival of Adrenocortical Carcinoma in Denmark 2003-2019
Pedersen, J., Jarløv, A. E., Rasmussen, Å. K., & Stochholm, K. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae012 · Cited by 12
Beuschlein, F., Jakoby, J., Mentz, S., Zambetti, G. P., Jung, S., Reincke, M., Süss, R., & Hantel, C. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.03.023 · Cited by 12
Adrenalectomy for incidentaloma: lessons learned from a single‐centre series of 274 patients
Gaujoux, S., Aimé, A., Assié, G., Ciuni, R., Bonnet, S., Tenenbaum, F., Bertherat, J. Y., & Dousset, B. E. (2017) · ANZ Journal of Surgery · doi:10.1111/ans.14095 · Cited by 12
Self-citationParikh, P. P., Rubio, G. A., Farrá, J. C., & Lew, J. I. (2017) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2017.08.018 · Cited by 12
Metadata
- Authors
- Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J.
- Affiliations
- Hôpital Cochin (FR)
- Centre National de la Recherche Scientifique (FR)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-07
- Volume
- 91
- Issue
- 7
- Pages
- 2650-2655
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2140991656
- Cited by
- 435
- References
- 34
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 14 · 2023: 23 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 23 · 2018: 33 · 2017: 17 · 2016: 23 · 2015: 32 · 2014: 31 · 2013: 21 · 2012: 18
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, prognosis, prognostic factors, survival, liver metastasis, lung metastasis, age at diagnosis, mitotane, adjuvant chemotherapy, androgen-secreting tumor
- MeSH terms
- Adrenal Cortex Neoplasms, Adult, Analysis of Variance, Androgens, Bone Neoplasms, Female, Humans, Hydrocortisone, Liver Neoplasms, Lung Neoplasms, Male, Middle Aged, Mitotane, Neoplasm Staging, Prognosis, Survival Rate, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
